.jpg "LivaNova PLC (NASDAQ: LIVN)")
In a report released today, Michael Matson from Needham reiterated a Buy rating on LivaNova PLC (LIVN), with a price target of $91. The company’s shares closed last Monday at $79.68.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 6.7% and a 62.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies Inc, Boston Scientific Corp, and Cardiovascular Systems.
LivaNova PLC has an analyst consensus of Moderate Buy, with a price target consensus of $91.
See today’s analyst top recommended stocks >>
Based on LivaNova PLC’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $29.22 million. In comparison, last year the company had a net profit of $15.28 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others.
